TalpheraTLPH
Recorded

Talphera 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration40 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Talphera Q3 2026 Financial Results Conference Call. This call is being webcast live via the events page of the investor section of Talphera's website at www.talphera.com. You may listen to a replay of this webcast by going to the investor section of Talphera's website. I would now like to turn the call over to Raffi Asadorian, Talphera's Chief Financial Officer.

Raffi AsadorianCFO

Please go ahead. Thank you for joining us on the call today.

Raffi AsadorianCFO

Today, we announced our third quarter 2026 financial results and associated business updates in a press release. With me today are Vince Angotti, our Chief Executive Officer, and Dr. Shakil Aslam, Talphera's Chief Medical Officer. Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Talphera. Please refer to our press release, in addition to the company's periodic current and annual reports filed with the Securities and Exchange Commission, for a discussion of the risks associated with such forward-looking statements. These documents can also be found on our website within the Investors section. I'll now hand the call over to Vince.

Vincent AngottiCEO

Thanks, Raffi. Good afternoon, and thank you to everyone joining our call today. I'll begin with an update on our NEPHRO-CRRT registrational study evaluating Niyad, our investigational nafamostat-based regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy, or CRRT. This study is being conducted in U.S. hospital ICUs with nephrologists as principal investigators. We recently submitted a briefing document to the FDA requesting a Sprint Meeting to discuss our proposed approach to closure of the study by December 31, 2026. I'll explain the rationale for our request and then provide an update on Niyad's commercial opportunity. Over the past several quarters, we've made meaningful progress in advancing the NEPHRO study. Enrollment has now exceeded 75% of our planned target, as we reported last quarter. In recent months, enrollment has been unexpectedly slow due to fewer qualifying patients.

Vincent AngottiCEO

Other CRRT studies have recently faced similar enrollment challenges, reflecting the difficulties of conducting clinical trials involving critically ill patients in the intensive care unit. Importantly, as a result of the slower enrollment dynamics in the industry, there is precedent for CRRT studies closing enrollment early and subsequently obtaining regulatory approval. Given these dynamics, we've taken a proactive approach to pursue the most efficient path forward for the NEPHRO study. To that end, we recently submitted a Sprint Meeting request to the FDA seeking its agreement to conclude enrollment by December 31, 2026, with the number of evaluable patients enrolled at that time. This would be instead of completing the originally planned target of 70 patients, should we not reach that number by the end of the year. Notably, based on our current enrollment, the study is over 80% powered for the primary endpoint.

Vincent AngottiCEO

This is a meaningful consideration in evaluating the appropriate sample size for the study. It provides additional scientific support for our proposal to conclude enrollment early, particularly given the challenges associated with enrolling critically ill patients in the ICU. Above all, our objective is to maintain the study integrity while avoiding unnecessary delays and advancing Niyad toward a potential regulatory submission. We have requested a Sprint Meeting, submitted the supporting briefing document, and presented our proposed approach to the FDA. Based on Niyad's Breakthrough Device Designation, our historical interactions with the FDA, and the statutory timing, we would anticipate feedback will be provided by the end of this year. Top-line data are expected within four to six weeks after enrollment is completed. Now, turning to the commercial opportunity, we are increasingly encouraged by the potential market for Niyad in the U.S.

Vincent AngottiCEO

Following further evaluation of the CRRT market, we have increased our estimate of Niyad's peak annual U.S. sales for use during CRRT to now exceed $200 million. This is based on formal feedback from physicians via quantitative and qualitative research. The research included expected anticoagulant treatment utilization and the unique characteristics of nafamostat. It also addressed the potential role of nafamostat in overcoming the limitations of existing anticoagulation approaches. We believe Niyad's differentiated profile, together with the significant unmet need in CRRT anticoagulation, positions it to address a substantial market opportunity if approved. Furthermore, a recent study published in the New England Journal of Medicine compared CRRT with intermittent hemodialysis in critically ill patients with acute kidney injury. The study was stopped early, as it found higher mortality among patients receiving intermittent hemodialysis.

Vincent AngottiCEO

This is the first study of its kind to provide clinical outcomes evidence favoring CRRT over intermittent hemodialysis in this patient population in the hospital. We believe the findings could support further growth of the overall CRRT market. In addition, as we discussed last quarter, the updated draft guidelines from KDIGO, which stands for Kidney Disease: Improving Global Outcomes, elevated nafamostat as an alternative anticoagulant for CRRT when citrate cannot be used. We believe this recognition highlights nafamostat's potential role in addressing the limitations of existing anticoagulation options. Together, these developments provide additional support for the commercial opportunity we see for Niyad, if approved. With that, I will hand the call over to Raffi to update you on the financial results for the third quarter.

Raffi AsadorianCFO

Thank you, Vince. Our cash balance at September 30, 2026, was $14.2 million. We believe this cash, combined with future conditional financing tranches, will provide us sufficient capital through at least a potential Niyad PMA approval expected in 2027. Two conditional financing tranches remain, totaling approximately $16 million of additional capital. If the conditions are met, we expect these to close around the time we release our top-line data and announce completion of the study. Our operating expenses, or combined R&D and SG&A expenses, excluding non-cash stock-based compensation expense, for the third quarter of 2026 totaled $3.8 million, compared to $3.3 million for the third quarter of 2025. The $0.5 million increase in cash operating expenses in the third quarter of 2026 was primarily due to higher Niyad development expenses and certain SG&A expenses related to pre-launch commercial preparation activities.

Raffi AsadorianCFO

As a note, we plan to file a Form S-3 shelf registration statement to replace our existing Form S-3 that expires on November 30, 2026. I'll now turn the call back to Vince.

Vincent AngottiCEO

Thank you, Raffi. We're enthusiastic about the potential of nafamostat and the progress made with the NEPHRO-CRRT program. Our recent submission requesting an FDA Sprint Meeting under the Breakthrough Devices Program reflects our proactive approach to determining the most appropriate regulatory path forward. Supported by the study's current statistical power and relevant regulatory precedent, we believe our proposal provides a sound basis for discussion with the agency. We value our ongoing collaboration with the FDA and look forward to the agency's feedback on our proposed approach. Our updated market research has increased our estimate of peak annual U.S. sales for nafamostat in CRRT to more than $200 million, reinforcing our confidence in Niyad's commercial potential. We look forward to discussing this opportunity in greater detail at our investor and analyst event planned for the first quarter of 2027.

Vincent AngottiCEO

We appreciate the continued support of our investors and look forward to keeping you updated on our progress. I'd like to open the line for any questions you may have.

Operator

Operator? Thank you. Ladies and gentlemen, we will now begin the question-and-answer session.

Operator

Should you have a question, please press star followed by the number 1 on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press star followed by the number 2. If you are using a speakerphone, please lift the handset before pressing any keys. Your first question comes from Ed Arce with WestPark Capital.

Ed ArceAnalyst

Please go ahead. Hi. Good afternoon, guys, Vince and Raffi.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day